I MAB【IMAB】銘柄情報

I MAB (IMAB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

4.63

( - )

買値

4.50

売値

4.60

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

前日終値

4.63

始値

時刻

最終取引時間

平均取引量 (3 か月)

財務取引量

VWAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

IMAB - Frequently Asked Questions (FAQ)

What is the current I MAB share price?

The current share price of I MAB is US$ 4.63

What is the 1 year trading range for I MAB share price?

I MAB has traded in the range of US$ 0.00 to US$ 0.00 during the past year

glenn1919 8月前

IMAB..........................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 9月前

IMAB.............................................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 9月前

IMAB.............................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 10月前

IMAB.........................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 10月前

IMAB..............................................................p/m

👍️0

glenn1919 10月前

IMAB...................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 12月前

IMAB........................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

TrendTrade2016 12月前

IMAB 3.10 MAGNET SELL OPP

👍️0

TrendTrade2016 12月前

IMAB MONSTER BIO BREAKING THE 2.95 PIVOT

👍️0

TrendTrade2016 12月前

IMAB 2.95 PRECISION MAGENT CALL....WATCH AND LEARN

👍️0

TrendTrade2016 12月前

IMAB 2.95 MAGNET...PRECISION TRADING ONLY TAKES PLACE UNDER MY CONTROL...NOBODY ON THIS SITE CAN READ CHARTS

👍️0

TrendTrade2016 12月前

IMAB 2.75 MAGNET CALL 2.95 CAN WE DO IT?!!!!!!

👍️0

TrendTrade2016 12月前

IMAB...HEE COMES THE MAGNET PULLING HER UP FAST

👍️0

TrendTrade2016 1年前

IMAB RESISTANCE BROKE...MAGNET UP A HEAD

👍️0

TrendTrade2016 1年前

IMAB BIO BEAST...2.58 RISISATANCE BREAK AND SHE FLYS TO 2.95

👍️0

TrendTrade2016 1年前

IMAB WEEKLY BREAK ABOVE THE CLOUD

👍️0

glenn1919 1年前

IMAB.......................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 1年前

IMAB.......................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 1年前

IMAB.......................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2年前

IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2年前

IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

👍️0

AGORDON 2年前

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

👍️0

AGORDON 2年前

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

👍️0

AGORDON 2年前

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

👍️0

AGORDON 2年前

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

👍️0

AGORDON 2年前

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

👍️0

AGORDON 3年前

The stock has bounced off $1.80 two times within a month.

👍️0

AGORDON 3年前

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

👍️0

Mt. Blanc 3年前

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

I MAB (IMAB)

I MAB (IMAB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

IMAB 最新ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

IMAB - Frequently Asked Questions (FAQ)

IMAB 取引

IMAB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR